Physician profile
Mona Dalia
NPI 1255833059
$1,658.21
in general payments reported to CMS, 2019-2025
15 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $295 · 2023: $344 · 2024: $343 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $437.19 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $236.46 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $232.87 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $169.61 | 2022-2023 | Repatha |
| Exact Sciences Corporation | $143.48 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $104.03 | 2022-2025 | |
| Glaxosmithkline, LLC. | $77.53 | 2021-2024 | Arexvy |
| Abbvie INC. | $64.75 | 2021-2025 | |
| Amarin Pharma, INC. | $42.75 | 2021 | |
| Pfizer INC. | $41.82 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.76 | 2021-2022 | |
| Eisai INC. | $20.35 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.95 | 2022 | |
| Acella Pharmaceuticals, LLC | $14.67 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Dalia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.